Free Classifieds at USNetAds.com - View Item Content by ID 131828024
USNetAds > Health & Beauty > Health Services > Item ID 131828024
Item ID 131828024 in Category: Health & Beauty - Health Services
Cannot view this item. It could be pending, expired or deleted.
Below item is randomly selected from the same category and may have similar content.
Eli Lilly Debuts Mounjaro in India, Outpaces Novo Nordisk | |
Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, making it the first to introduce the medication in the country, ahead of rival Novo Nordisk. Mounjaro, a once-weekly injection, has been approved by India’s drug regulator and is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial. The highest dose available is 15 mg. Patients may spend about $200 a month for a weekly 5 mg dose, which is substantially lower than its U.S. price of $1,086.37 per month. Mounjaro, also known as tirzepatide, is used for both diabetes management and weight loss in various regions. In the U.S. it is sold under the name Zepbound for obesity, while in the UK and Europe, it is marketed for both conditions under the Mounjaro brand. Despite this, Lilly noted that prices differ significantly across regions due to various healthcare systems, economies, and reimbursement policies. This launch positions Lilly ahead of Novo Nordisk, which has yet to introduce its weight-loss drug Wegovy in India but aims for a 2025 launch, earlier than its previously targeted 2026. Wegovy, which contains the active ingredient semaglutide, and Mounjaro, both belong to the GLP-1 receptor agonists class, known for controlling blood sugar and promoting fullness. In India, obesity and diabetes rates are rising. The number of adults with diabetes is expected to surpass 124 million by 2045, up from 74.2 million in 2021. Additionally, a 2019-2021 survey revealed that 24% of women and 23% of men between 15 and 49 were overweight or obese. Lilly’s President in India, Winselow Tucker, emphasized that the growing prevalence of these health issues makes Mounjaro a critical addition to the market. For more details please visit our website - https://www.medhealthinsight.com/eli-lilly-debuts-mounjaro-in-india-outpaces-novo-nordisk/  | |
| Related Link: Click here to visit item owner's website (0 hit) | |
| Target State: New York Target City : New York City Last Update : Jun 26, 2025 5:33 AM Number of Views: 7 | Item Owner : medhealthinsight Contact Email: (None) Contact Phone: (None) |
| Friendly reminder: Click here to read some tips. | |
USNetAds > Health & Beauty > Health Services > Item ID 131828024
© 2025 USNetAds.com
GetJob.us | CANetAds.com | UKAdsList.com | AUNetAds.com | INNetAds.com | CNNetAds.com | Hot-Web-Ads.com | USAOnlineClassifieds.com
2025-06-26 (0.572 sec)